(Circulation. 1999;99:406-410.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Cardiology, University of Western Ontario, London, Ontario, Canada, and Medtronic, Minneapolis, Minn (T.T.-N.).
| Abstract |
|---|
|
|
|---|
Methods and ResultsWe used a prolonged monitoring strategy to determine the cause of syncope in 85 patients (age, 59±18 years; 44 men) with recurrent undiagnosed syncope with an implantable loop recorder capable of cardiac monitoring for up to 18 months. During a mean of 10.5±4.0 months of follow-up, symptoms recurred in 58 patients (68%) 71±79 days (2.3±2.6 months) after implantable loop recorder insertion. An arrhythmia was detected in 42% of patients who recorded a rhythm during recurrent symptoms, with bradycardia present in 18 and tachycardia in 3. Five of the 18 bradycardic patients and 2 additional sinus rhythm patients received a clinical diagnosis of neurally mediated syncope. Patients who experienced presyncope were much less likely to record an arrhythmia during symptoms compared with recurrence of syncope (24% versus 70%, P=0.0005). There were no adverse events associated with recurrent symptoms, and there were no sudden deaths. Inability to freeze after an event occurred in 8 patients, and pocket infection occurred in 3.
ConclusionsThe strategy of prolonged monitoring is effective and safe in patients with problematic syncope.
Key Words: syncope arrhythmia diagnosis
| Introduction |
|---|
|
|
|---|
A symptom-rhythm correlation is often difficult to obtain during spontaneous episodes because of the sporadic, infrequent, and unpredictable nature of syncope. Despite a wide array of diagnostic tools, the cause of syncope is not determined after initial investigations in 38% to 47% of patients.6 13 14 Even after referral for tilt-table and electrophysiological testing, 10% to 26% of patients will remain undiagnosed.2 15 16
Recent advances in loop recorder technology have permitted a longer duration of external ECG monitoring than conventional Holter monitoring, improving the overall diagnostic yield.7 10 11 12 We used a new insertable loop recorder (ILR) that can provide monitoring for 14 months to assess the utility and safety of a prolonged monitoring strategy in a multicenter study of 85 syncopal patients without a diagnosis after initial assessment.
| Methods |
|---|
|
|
|---|
|
Previous Investigations
Testing before patient enrollment in the study was performed at
the discretion of the investigator (Table 1
). All patients
underwent clinical assessment, including ambulatory or in-hospital
monitoring. Of the 85 patients, 21 had been referred to an internist
and 73 had been referred to another cardiologist before assessment by
the study investigator. Most patients had several investigations for
syncope before ILR insertion, the most common of which were
echocardiography, head-up tilt testing, and
electrophysiological testing. One patient
had experienced a previous cardiac arrest and underwent extensive
investigation, including
electrophysiological testing, before
enrollment in the study.
Device
The ILR is a 61x19x8-mm recording device with 2
sensing bipoles 37 mm apart within its shell. It weighs 17 g
and has a volume of 8 cm3, slightly smaller than
a standard VVI pacemaker. The recorded ECG signal is stored in a
circular buffer capable of retaining 21 minutes of uncompressed signal
or 42 minutes of compressed signal in 1 or 3 divided parts. The memory
buffer is frozen with a hand-held activator provided to the
patient at the time of device implantation. The resultant programming
can store a single episode of 21 minutes (20 minutes before and 1
minute after "freeze"), a 42-minute compressed episode (40 minutes
before, 2 minutes after), three 7-minute episodes (6 minutes before, 1
minute after), or three 14-minute compressed episodes (12 minutes
before, 2 minutes after). The episodes are then downloaded after
interrogation with a standard pacemaker programmer (Medtronic
9790C).
Investigators performed device implantation in an operating room, cardiac catheterization laboratory, electrophysiology laboratory, or specialized procedure room at their discretion. The site of the implant was generally in the left infraclavicular region but was determined in each circumstance by patient and physician preference. Use of prophylactic antibiotics was left to the discretion of the implanting physician. After the skin was infiltrated with local anesthesia, a 2-cm incision was made. A pocket was fashioned, and the device was inserted and anchored with a nonabsorbable suture. The skin was closed with absorbable sutures, and a satisfactory R-wave signal was verified with the programming head applied over the implanted device. The patient, along with a spouse, family member, or friend, was instructed in the use of the activator at the time of implantation. Patients were instructed to activate the device in the event of syncope or presyncope. Follow-up was performed after each event. The device remained implanted until syncope or presyncope recurred unless the patient or investigator chose to remove it sooner. Devices were removed after 18 months of follow-up or at end of battery life.
Analysis
Continuous variables were compared by Student's
t tests, and categorical variables were compared by a
2 test. A value of P<0.05 was
considered significant.
| Results |
|---|
|
|
|---|
Symptom-Rhythm Correlation
An arrhythmia was detected in 21 of the 50 patients (42%)
who recorded a rhythm during recurrent symptoms, with bradycardia
being the most frequent (Figure 1
). Of
the 18 patients with bradycardia (heart rate <50 bpm), 12 underwent
device removal and pacemaker implantation. Five of the 18 patients had
heart rate slowing, which the investigator interpreted as the
cardioinhibitory component of neurally mediated syncope.
Two additional patients had relative slowing, with a heart rate >50
bpm, and also received a clinical diagnosis of neurally mediated
syncope (Figure 2
). Three patients had
tachyarrhythmias associated with recurrent symptoms:
sustained supraventricular tachycardia in 2
patients, who subsequently underwent catheter ablation, and atrial
flutter with a rapid ventricular response in 1 patient, who
received pharmacological therapy. The remaining 29 patients had sinus
rhythm during symptomatic recurrence and continue
to be followed up. Devices remained implanted in these patients to
monitor subsequent episodes.
|
|
Syncope Versus Presyncope
Of the 50 patients with a symptom-rhythm correlation, 13 had
syncope, 10 had recurrence of syncope and presyncope, and 27
had presyncope alone. When patients experienced presyncope, they were
much less likely to record an arrhythmia during symptoms
compared with recurrence of syncope (24% versus 70%,
P=0.0005, Figure 3
). When
those patients with a clinical diagnosis of neurally mediated syncope
(n=4) or presyncope (n=4) were excluded, the difference remained
significant (24% versus 63%, P=0.006). Arrhythmias
were seen in 9 of the 13 patients (69%) who had recurrence of
syncope alone (without other presyncopal events), with bradycardia
recorded in all 9 patients during syncope. In the 10 patients with
both syncope and presyncope, syncope was associated with an
arrhythmia in 7 (bradycardia in 5, tachycardia in
2), whereas presyncope documented an arrhythmia in only 4
patients (bradycardia in 2, tachycardia in 2). The 3
patients with an arrhythmia during presyncope had the same
arrhythmia during syncope.
|
Device
The majority of devices were implanted outside of an operating
room setting (Table 2
). The device was
inserted in the left pectoral region near a traditional pacemaker
implant site in 64% of patients. Of the remaining 31 devices, 27 were
implanted in the left inframammary region. The mean implant voltage was
481±279 µV for all 85 patients. An adequate electrogram was obtained
in all 85 patients (range, 58 to 1300 µV). The signal-to-noise ratio
was 19:1. P waves were seen in 37% of vertical implants, compared with
14% of horizontal ones. The sensed amplitude was 831±343 µV at the
single center at which systematic surface mapping was performed before
implantation to optimize the sensed signal amplitude.
|
Two patients who did not receive prophylactic antibiotics developed local infection requiring treatment with oral antibiotics after device removal. A second device was reimplanted in another site in 1 of these patients. A third patient had persistent pain at a left inframammary implant site, which resolved when the device was moved to the left pectoral region. A fourth patient developed local erosion with infection 13 weeks after implantation. The device was explanted without incident. No patient requested removal of the device before recurrence of symptoms. The devices were removed at the end of follow-up without complications.
Outcome
During the study, 1 patient died of myocardial infarction that was
not complicated by arrhythmias. A second patient died of cancer
of the lung, and a third patient suffered a cerebrovascular accident
and withdrew from the study.
| Discussion |
|---|
|
|
|---|
In a previous pilot study of 24 patients with syncope, a prototype implantable loop recorder established the cardiac rhythm in all 21 patients who had recurrent syncope after the device was implanted.15 This population represented a difficult subgroup with refractory but infrequent syncope that was not diagnosed after extensive testing. The present study examined the utility of the ILR in a multicenter study. The patient population was selected to be more representative of those referred to cardiologists or electrophysiologists for investigation of syncope after a workup that varied according to physician preference.
The strategy of prolonged monitoring was successful in establishing a symptom-rhythm correlation in 86% of the 58 patients who had recurrence during the follow-up period. The rhythm profile of patients during recurrent syncope reflected an arrhythmic cause in 42% of patients, in keeping with the findings of the pilot study (48%). In the remaining patients, an arrhythmia was eliminated as a potential cause of symptoms, alleviating concerns of a life-threatening arrhythmia.
The absence of sudden death or significant morbidity suggests that this observational approach was safe in the population studied and did not place patients at risk during spontaneous recurrence. This is of particular interest given the prevalence of significant structural heart disease, the major determinant of prognosis in syncopal patients.3 Sixty-two percent of patients had some structural heart disease, with 19% having documented coronary artery disease, previous cardiac arrest, or left ventricular dysfunction. Investigator selection and preceding negative investigations, including electrophysiological testing in some patients, may have screened out those patients at higher risk of life-threatening arrhythmias. This does not necessarily imply that a monitoring strategy is safe in all patients. For example, patients with poor left ventricular function and inducible ventricular tachycardia at electrophysiological testing have been shown to receive appropriate shocks when managed with an implantable defibrillator.22 A proactive approach using electrophysiological testing in this population seems reasonable.
Symptoms did not recur in 32% of patients over 10 months of follow-up. This spontaneous resolution is in keeping with other series, which have noted a 57% to 85% resolution during 10 to 40 months of follow-up after negative initial investigations.1 2 21 23 24 This finding may relate to the spontaneous periodicity of syncope, a self-limited cause, or a screening effect of the completed investigations, which have identified the causes of syncope that are most likely to recur.
The occurrence of presyncope is often clinically interpreted as "imminent" syncope. It is tempting to use presyncope as a surrogate for syncope. The predictive value of presyncope in establishing an arrhythmic cause for symptoms was low. Excluding patients with a diagnosis of neurally mediated syncope, only 24% of patients with presyncope were found to have an arrhythmia (versus 63% for syncope). The majority of patients (76%) reporting presyncope were in sinus rhythm. In those patients with both presyncope and syncope, presyncope was misleading in 3 of the 6 patients with sinus rhythm during presyncope who subsequently had an arrhythmia documented in conjunction with frank syncope. Others have similarly reported a low yield for external monitoring in patients with presyncope,25 although data on the relationship between presyncope and syncope in the same patients remain scant.
Individual investigators each implanted 1 to 4 devices, with the
exception of a single site, at which 11 devices were implanted. Despite
the absence of a learning period with respect to implantation
technique, the relatively low complication rate suggests that the
procedure is readily adopted by operators experienced with implantable
devices. The unexpected infection rate may reflect the need for routine
antibiotic prophylaxis, which was not required in the study.
Programming and interrogation were performed with a pacemaker
programmer, which is accessible to most pacing centers. Patient-related
difficulties with freezing after events occurred in 16% of patients.
Of these patients,
50% subsequently froze appropriately. This
problem may be minimized in the future by development of autodetection
functions, improved patient education, and expanded memory capacity.
Similar difficulties with freezing have been reported in 32% of
patients using an external loop recorder,7 10 in whom
device malfunction, patient noncompliance, or inability to
activate the recorder was responsible for the lack of
success. External devices suffer from insufficient memory for many
patients who are unable to activate the device within 4 to 6
minutes of syncope, as well as waning patient compliance with external
electrodes in the absence of a diagnosis.
Limitations
The population under study represents a spectrum of
individuals referred to a cardiologist or electrophysiologist for
evaluation. Although they may not represent a primary syncope
population, they served to test the utility of a prolonged monitoring
strategy in patients with recurrent syncope. Second, obtaining a
symptom-rhythm correlation does not necessarily lead to a diagnosis.
Nonetheless, exclusion of arrhythmia often alleviates the
concerns of both the patient and physician regarding the potential for
life-threatening arrhythmias and allows the focus of further
investigations (if necessary) to shift to other areas. Finally, a small
proportion of patients were unable to activate the device after
a spontaneous event. Future iterations should include programmable
automatic detection algorithms and longer memory loops. In addition,
monitoring of other physiological
parameters, such as blood pressure and oxygen saturation,
is a feasible goal. Current development suggests that device size may
decrease by 30% to 60%, facilitating implantation in an office
setting by operators with less surgical experience.
Conclusions
The strategy of prolonged monitoring is effective in establishing
a symptom-rhythm correlation in the majority of patients with
problematic syncope. It obviates the need for difficult
interpretation of provocative testing. Presyncope is much
less likely to be associated with an arrhythmia than syncope
and did not prove to be an accurate surrogate for syncope in
establishing a diagnosis.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 See Appendix for list of investigators. ![]()
| Appendix 1 |
|---|
|
|
|---|
Received April 21, 1998; revision received September 17, 1998; accepted October 9, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. H Pass and L. Liberman The implantable loop recorder in children: searching for indications Heart, July 1, 2008; 94(7): 832 - 833. [Full Text] [PDF] |
||||
![]() |
B Yeung and K McLeod The implantable loop recorder in children Heart, July 1, 2008; 94(7): 888 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Pierre, L. Fauchier, G. Breard, O. Marie, P. Poret, and D. Babuty Implantable loop recorder for recurrent syncope: influence of cardiac conduction abnormalities showing up on resting electrocardiogram and of underlying cardiac disease on follow-up developments Europace, April 1, 2008; 10(4): 477 - 481. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-E. Claesson, B.-E. Kristensson, N. Edvardsson, and P. Wahrborg Less syncope and milder symptoms in patients treated with pacing for induced cardioinhibitory carotid sinus syndrome: a randomized study Europace, October 1, 2007; 9(10): 932 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maggi, C. Menozzi, M. Brignole, C. Podoleanu, M. Iori, R. Sutton, A. Moya, F. Giada, S. Orazi, and N. Grovale Cardioinhibitory carotid sinus hypersensitivity predicts an asystolic mechanism of spontaneous neurally mediated syncope Europace, August 1, 2007; 9(8): 563 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF] |
||||
![]() |
F. Enseleit and F. Duru Long-term continuous external electrocardiographic recording: a review. Europace, April 1, 2006; 8(4): 255 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Deharo, C. Jego, A. Lanteaume, and P. Djiane An Implantable Loop Recorder Study of Highly Symptomatic Vasovagal Patients: The Heart Rhythm Observed During a Spontaneous Syncope Is Identical to the Recurrent Syncope But Not Correlated With the Head-Up Tilt Test or Adenosine Triphosphate Test J. Am. Coll. Cardiol., February 7, 2006; 47(3): 587 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Farwell, N. Freemantle, and N. Sulke The clinical impact of implantable loop recorders in patients with syncope Eur. Heart J., February 1, 2006; 27(3): 351 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sreeram, F. Hitchcock, and G. Bennink Abdominal Implantation of Loop Recorders in Infants and Children Ann. Thorac. Surg., February 1, 2005; 79(2): 726 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.J. Farwell, N. Freemantle, and A.N. Sulke Use of implantable loop recorders in the diagnosis and management of syncope Eur. Heart J., July 2, 2004; 25(14): 1257 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N Simantirakis, S. I Schiza, M. E Marketou, S. I Chrysostomakis, G. I Chlouverakis, N. C Klapsinos, N. S Siafakas, and P. E Vardas Severe bradyarrhythmias in patients with sleep apnoea: the effect of continuous positive airway pressure treatment: A long-term evaluation using an insertable loop recorder Eur. Heart J., June 2, 2004; 25(12): 1070 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Boersma, L.ís Mont, A. Sionis, E. García, and J. Brugada Value of the implantable loop recorder for the management of patients with unexplained syncope Europace, January 1, 2004; 6(1): 70 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Krahn, G. J. Klein, R. Yee, J. S. Hoch, and A. C. Skanes Cost implications of testing strategy in patients with syncope: Randomized assessment of syncope trial J. Am. Coll. Cardiol., August 6, 2003; 42(3): 495 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Kurer Implantable looprecorders: dollars and sense J. Am. Coll. Cardiol., August 6, 2003; 42(3): 502 - 504. [Full Text] [PDF] |
||||
![]() |
J R Gimbel Novel use of an "insertable" loop recorder Heart, June 1, 2003; 89(6): e18 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. N. Kapoor Is There an Effective Treatment for Neurally Mediated Syncope? JAMA, May 7, 2003; 289(17): 2272 - 2275. [Full Text] [PDF] |
||||
![]() |
S. I. Chrysostomakis, N. C. Klapsinos, E. N. Simantirakis, M. E. Marketou, D. C. Kambouraki, and P. E. Vardas Sensing issues related to the clinical use of implantable loop recorders Europace, January 1, 2003; 5(2): 143 - 148. [Abstract] [PDF] |
||||
![]() |
W. H. Maisel and W. G. Stevenson Syncope -- Getting to the Heart of the Matter N. Engl. J. Med., September 19, 2002; 347(12): 931 - 933. [Full Text] [PDF] |
||||
![]() |
C. Menozzi, M. Brignole, R. Garcia-Civera, A. Moya, G. Botto, L. Tercedor, R. Migliorini, X. Navarro, and on behalf of the International Study on Syncope of Mechanism of Syncope in Patients With Heart Disease and Negative Electrophysiologic Test Circulation, June 11, 2002; 105(23): 2741 - 2745. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Chrysostomakis, E. N. Simantirakis, M. E. Marketou, and P. E. Vardas Implantable loop recorder undersensing mimicking complete heart block Europace, January 1, 2002; 4(2): 211 - 213. [Abstract] [PDF] |
||||
![]() |
A. Moya, M. Brignole, C. Menozzi, R. Garcia-Civera, S. Tognarini, L. Mont, G. Botto, F. Giada, and D. Cornacchia Mechanism of Syncope in Patients With Isolated Syncope and in Patients With Tilt-Positive Syncope Circulation, September 11, 2001; 104(11): 1261 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Pires, J. R. Ganji, R. Jarandila, and R. Steele Diagnostic Patterns and Temporal Trends in the Evaluation of Adult Patients Hospitalized With Syncope Arch Intern Med, August 13, 2001; 161(15): 1889 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450. [PDF] |
||||
![]() |
A. D. Krahn, G. J. Klein, R. Yee, and A. C. Skanes Randomized Assessment of Syncope Trial : Conventional Diagnostic Testing Versus a Prolonged Monitoring Strategy Circulation, July 3, 2001; 104(1): 46 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. BRIGNOLE, C. MENOZZI, A. MOYA, and R. GARCIA-CIVERA Implantable loop recorder: towards a gold standard for the diagnosis of syncope? Heart, June 1, 2001; 85(6): 610 - 612. [Full Text] |
||||
![]() |
W Arthur and G C Kaye Current investigations used to assess syncope Postgrad. Med. J., January 1, 2001; 77(903): 20 - 23. [Full Text] |
||||
![]() |
W. N. Kapoor Syncope N. Engl. J. Med., December 21, 2000; 343(25): 1856 - 1862. [Full Text] |